Bioequivalence study of α-dihydroergocryptine: Utility of metabolite evaluation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 1, 1996, Pages 32-37

  Ezan, E ^a,d   Ardouin, T ^a   Delhotal Landes, B ^b   Flouvat, B ^b   Hanslik, T ^b   Legeai, J M ^c   Grognet, J M ^a  

^a Institut National de la Recherche Agronomique   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c Laboratoires Jacques Logeais   (France)

^d DIF   (France)

Author keywords

Bioequivalence; Dihydroergocryptine; Immunoassay; Metabolites; Vasobral

Indexed keywords

DIHYDROERGOCRYPTINE; DRUG METABOLITE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECISION MAKING; DRUG ABSORPTION; DRUG DETERMINATION; DRUG FORMULATION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DIHYDROERGOTOXINE; HUMANS; MALE; THERAPEUTIC EQUIVALENCY;

EID: 0030070953     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Aellig WH, Nüesch E 1977 Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol 15: 106-112
2. Berde B, Schild HO 1978 Ergot alkaloids and related compounds Handbook of pharmacology (Vol 49). Springer, Berlin
3. Blume HH, Midha KK 1993 Biointernational '92, conference on bioavailability. bioequivalence and pharmacokinetic studies. Eur J Pharma Sci 1: 165-173
4. Collignon F, Pradelles P 1984 Highly sensitive and specific radioimmunoassays for α-dihydroergotoxine components in plasma Eur J Nucl Med 9: 23-27
5. Delaforge M, Rivière R, Sartort E, Doignon J-L, Grognet J-M 1989 Metabolism of dihydroergotamine by a cytochrome P-450 similar to that involved in the metabolism of macrolide antibiotics. Xenobiotica 19: 1285-1295
6. Diletti E, Hauschke D, Steinijans VW 1991 Sample size determination for bioequivalence assessement by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29: 1-8
7. 3H-dihydroergocryptine (DHEC) in the rat. Arzneimittel Forsch 30: 1887-1888
8. Eckert H, Kiechel JR, Rosenthaler J, Schmidt R, Schreier E 1978 Biopharmaceutical aspect. In: Berde B, Schild HO (eds). Handbook of pharmacology Vol 49: Ergot and related compounds. Springer, Berlin, pp 719-796
9. Ezan E, Mamas S, Rangeot C, Dray F 1987 Strategies for developing specific and sensitive hapten radioimmunoassays. In: Patrono C, Peskar BA (eds) Handbook of pharmacology Vol 82: Radioimmunoassay in basic and clinical pharmacology. Springer, Berlin, pp 143-179
10. Grognet J-M, Istin M, Zanotti F, Mailland F, Coppi G 1991 Pharmacokinetics of α-dihydroergocryptine in rats after intravenous and oral administration. Arzneim Forsch 41: 689-691
11. Grognet J-M, Ezan E 1991 Dosage des alcaloides de l'ergot de seigle. Apport de l'immunologie analytique. Immunol Biol Spéc 29: 25-30
12. Kanto J 1983 Clinical pharmacokinetics of ergotamine, dihydroergotamine, ergotoxine, bromocriptine, methylsergide, and lergotrile. Int J Clin Pharmacol Ther Toxicol 21: 135-142
13. Legeai J-M, Benharkate MM, Duverger J P, Boulu RG 1981 Effects of dihydroergocryptine on mouse and rat resistance to acute anoxia: influence of repetition of treatment. Experientia 37: 292-293
14. Le Poncin M, Rapin J-P, Lamproglou I, Legeai J 1989 Simultaneous evaluation of amnesic retention blood flow, and brain metabolism following quantitative microembolization in the rat. J Cerebr Blood Flow Metab 9 (Suppl I): S147
15. Maurer G, Schreier E, Delaborde E, Loosli HR, Nufer R, Shukla AP 1982 Fate and disposition in animals and man. I: stucture elucidation of the metabolites Eur J Drug Metab Pharmacokinet 7: 281-292
16. Maurer G, Flick W 1984 Elucidation of the structure and receptor binding studies of the major primary metabolite of dihydroergotamine in man. Eur J Clin Pharmacol 26: 463-470
17. Merle M, Restrepo Y, Benharkate M, Legeai J-M 1985 Immediate and prolonged effects of dihydroergocryptine after experimental vascular microsurgery. Microsurgery 6: 49-52
18. Midha KK, Hubbard JW, McKay G, Hawes EM, Hsia D 1994 The role of metabolites in a bioequivalence study 1: Ioxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol 31: 177-183
19. Schulz HU, Steinijans VW 1991 Striving for standards in bioequivalence assessement: a review. Int J Clin Pharmacol Ther Toxicol 30: S1-S6
20. Shah VP, Midha KK, Dighe S, McGilveay IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan, Cook CE, McDonald RD, Pittman KA, Spector S 1991 Analytical methods of validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet 16: 249-255
21. Tucker GT, Rostani A, Jackson PR 1992 Metabolite measurement in bioequivalence studies. I. Theoretical considerations. Abstract, Bio International '92, Bad Homburg, Frankfurt, Germany 20-22 May, 1992
22. Walter-Sack I, de Vries JX, Kreiner C, Ittensohn A, Stenzhorn G, Voss A, Weber E 1993 Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite? Clin Invest 71: 240-246
23. Woodcock BG, Habedand WD, Loh W, Herrmann W, Rietbrock N 1987 Bioavailability of slow-release co-erdocrine mesylate (dihydroergotoxine) formulations Int J Clin Pharmacol Ther Toxicol 25: 660-663
24. Woodcock BG, Rietbrock N, Loh W, Habedand WD 1985 Absorption of dihydroergotoxine following oral administration to man. Br J Clin Pharmacol 20: 603-609
25. Wyss PA, Rosenthaler J, Nüesch E, Aellig WH 1991 Pharmacokinetic investigation of oral and IV dihydioergotamine in healthy subjects. Eur J Clin Pharmacol 41: 597-602